Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Apixaban

CAS No.

503612-47-3

Innovator/marketer

Eliquis

Polymorphic form

Crystalline form N-1

Therapeutic Area

Blood & blood forming organs

Status

Pipeline

EU DMF readiness

US DMF readiness

031166

Drug description:

Apixaban is a phenylpiperidine derivative, acts as antithrombotic or anticoagulant agent.
It is indicated to reduce the risk of stroke, systemic embolism in patients with non-valvular atrial fibrillation and for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery, treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism).
It is formulated as tablets and film-coated tablets for oral route of administration.

Mechanism of action:

Apixaban is an anticoagulant direct factor Xa inhibitor. It is a reversible direct and selective inhibitor of factor Xa, which inhibits free and clot-bound factor Xa and prothrombinase activity, leading to indirect inhibition of platelet aggregation induced by thrombin which is responsible for activating fibrinogen and allowing clot formation. Apixaban plays an important role in inhibiting blood coagulation and preventing thrombosis.

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK